Investing.comCodex · 实盘不做把握 5/10不做原因:无增量信息
北京时间·🕒 发布 19:08:41·⟳ 抓取 19:09:30 +49s·⚡ 决策 09-03 19:39:27 +29m57s·53.9 天前
Eledon提交tegoprubart胰岛细胞移植注册性研究IND，早期疗效数据此前已披露
事件方向偏正面，但主要临床数据、胰岛细胞注册性研究计划和肾移植3期时间表此前已在公司公告及SEC文件中披露；本次IND提交尚未等同FDA clearance，短线正期望不足。
📄 原文Investing.com↗ 原文
Eledon submits IND for tegoprubart islet cell transplant study
Oil pulls back, Broadcom disappoints - what’s moving markets IRVINE, Calif. - Eledon Pharmaceuticals Inc. (NASDAQ:ELDN)…
不做 Eledon Pharmaceuticals（ELDN.US）
不做Eledon Pharmaceuticals（ELDN.US）：IND提交是正面进展但不是FDA clearance，核心疗效与注册性研究计划此前已公开，融资约束仍在，短线edge不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Eledon的tegoprubart在胰岛细胞移植中已有强早期数据，IND提交推进了注册路径，但市场此前已见到12例100%胰岛素独立数据及公司将启动注册性研究的指引。本次增量是提交而非获批，且公司披露需额外融资支持胰岛细胞注册研究，因此不追ELDN.US。
消息传播链
- 报道称Eledon已提交tegoprubart胰岛细胞移植注册性研究IND申请；未在检索中命中同日公司IR原文。
- 公司此前已披露UChicago胰岛移植研究12名患者均达到胰岛素独立、HbA1c低于6.5%、最长随访22个月。
- 公司二季报已列出胰岛细胞移植注册路径研究启动计划，并披露现金可支持运营至2027年二季度。
关键理由
- tegoprubart若替代钙调神经磷酸酶抑制剂，有望改善移植免疫抑制方案，这是Eledon长期价值核心。
- 但本次新增只是IND submission，现有销售基数为临床期无产品收入，新增商业收入仍取决于FDA放行、试验启动、融资和多年临床结果。
- 6月已披露12例胰岛细胞移植患者均达到胰岛素独立，8月财报已提示将启动胰岛细胞注册路径研究。
主要风险
- FDA尚未披露IND clearance，若要求补充资料，本次正面叙事会被削弱。
- Eledon截至2026年6月现金及短投约8880万美元，预计仅支持运营至2027年二季度，胰岛细胞注册研究还需融资。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-13 · 影响 weakens
公司披露当前现金仅预计支持运营至2027年二季度，且胰岛细胞注册研究需额外融资。
检索:Eledon tegoprubart islet transplant financing risk cash runway registrational study 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-06-08 · 影响 weakens
本次报道中的关键疗效数据并非全新，6月公司已披露12例结果。
检索:Eledon tegoprubart islet cell transplant 12 patients insulin independence June 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足且本次增量弱，最终转为回避而非条件买入。
方向:未取得足够干净的同公司同阶段IND提交先例；既有公开记录更多是临床数据更新或IND clearance，而非仅提交。
涨幅量级:缺少高相似、首发锚干净且可测的样本，不能据此校准tp/sl。
形态:生物医药临床期小盘股对监管路径消息可能剧烈波动，但提交IND相对clearance和阳性数据更弱。
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 2,365 字
Oil pulls back, Broadcom disappoints - what’s moving markets
IRVINE, Calif. - Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) submitted an Investigational New Drug application to the U.S. Food and Drug Administration for a registrational clinical trial evaluating tegoprubart in type 1 diabetes patients undergoing pancreatic islet cell transplantation, according to a company press release issued today.
The planned study would be Eledon’s first company-sponsored clinical trial in islet cell transplantation. The company’s anti-CD40L antibody tegoprubart is being developed as an immunosuppression therapy for transplant patients.
The first patients have been enrolled in an investigator-initiated clinical trial at the University of Chicago Medicine Transplant Institute evaluating tegoprubart in patients with type 1 diabetes and renal dysfunction from chronic kidney disease receiving an islet cell transplant. The study examines a calcineurin inhibitor-free, tegoprubart-based immunosuppression regimen.
The first islet cell transplant recipient has been dosed with tegoprubart under a compassionate-use protocol to switch from tacrolimus-based immunosuppression therapy due to calcineurin inhibitor-related renal dysfunction.
UChicago Medicine is adding three patients to its ongoing investigator-initiated islet cell transplantation study, expanding beyond the 12 patients treated to date. Previously reported results showed all 12 patients with type 1 diabetes achieved insulin independence and a hemoglobin A1c level below 7.0% following islet cell transplantation and treatment with tegoprubart, with stable islet graft function observed through a maximum reported follow-up of 22 months.
In kidney transplantation, the first highly sensitized kidney transplant patient has been dosed with tegoprubart under a compassionate-use protocol at Duke University Medical Center. A third patient has been treated in an investigator-initiated study evaluating tegoprubart for kidney transplant tolerance induction at Massachusetts General Hospital.
Eledon stated it remains on track to initiate its global Phase 3 LEGACY trial of tegoprubart in kidney transplantation in the fourth quarter of 2026. The trial is expected to enroll approximately 600 patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
IRVINE, Calif. - Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) submitted an Investigational New Drug application to the U.S. Food and Drug Administration for a registrational clinical trial evaluating tegoprubart in type 1 diabetes patients undergoing pancreatic islet cell transplantation, according to a company press release issued today.
The planned study would be Eledon’s first company-sponsored clinical trial in islet cell transplantation. The company’s anti-CD40L antibody tegoprubart is being developed as an immunosuppression therapy for transplant patients.
The first patients have been enrolled in an investigator-initiated clinical trial at the University of Chicago Medicine Transplant Institute evaluating tegoprubart in patients with type 1 diabetes and renal dysfunction from chronic kidney disease receiving an islet cell transplant. The study examines a calcineurin inhibitor-free, tegoprubart-based immunosuppression regimen.
The first islet cell transplant recipient has been dosed with tegoprubart under a compassionate-use protocol to switch from tacrolimus-based immunosuppression therapy due to calcineurin inhibitor-related renal dysfunction.
UChicago Medicine is adding three patients to its ongoing investigator-initiated islet cell transplantation study, expanding beyond the 12 patients treated to date. Previously reported results showed all 12 patients with type 1 diabetes achieved insulin independence and a hemoglobin A1c level below 7.0% following islet cell transplantation and treatment with tegoprubart, with stable islet graft function observed through a maximum reported follow-up of 22 months.
In kidney transplantation, the first highly sensitized kidney transplant patient has been dosed with tegoprubart under a compassionate-use protocol at Duke University Medical Center. A third patient has been treated in an investigator-initiated study evaluating tegoprubart for kidney transplant tolerance induction at Massachusetts General Hospital.
Eledon stated it remains on track to initiate its global Phase 3 LEGACY trial of tegoprubart in kidney transplantation in the fourth quarter of 2026. The trial is expected to enroll approximately 600 patients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。